Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says erythropoietin clinical effect cannot be generalized to different tumor types without data from biopsies. Amgen's Aranesp will undergo five survival studies; J&J will look at Procrit and Eprex in metastatic breast cancer patients with an endpoint of progression-free survival.

You may also be interested in...



EPO Risks May Now Outweigh Benefits In Cancer Patients, FDA Documents Say

FDA briefing documents for May 10 Oncologic Drugs Advisory Committee meeting say evidence about the risks of mortality and tumors from use of erythropoiesis-stimulating agents has grown, while the products’ main benefit – reducing blood transfusions – is no longer as important as it once was.

EPO Risks May Now Outweigh Benefits In Cancer Patients, FDA Documents Say

FDA briefing documents for May 10 Oncologic Drugs Advisory Committee meeting say evidence about the risks of mortality and tumors from use of erythropoiesis-stimulating agents has grown, while the products’ main benefit – reducing blood transfusions – is no longer as important as it once was.

Amgen, J&J EPO Study Proposals On Tumor Progression To Be Reviewed By Cmte.

The Oncologic Drugs Advisory Committee will discuss the adequacy of the study proposals. The companies maintain that erythropoietin, when used for labeled indications, is not associated with an increased risk of mortality.

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel